REGENERON PHARMACEUTICALS, INC. Research and Development Expense
REGENERON PHARMACEUTICALS, INC. (REGN) reported Research and Development Expense of $1.63 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-30
- REGENERON PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-06-30 was $1.63B, a 14.76% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. research and development expense for the quarter ending 2026-03-31 was $1.54B, a 16.28% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-12-31 was $1.63B, a 15.15% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. research and development expense for the quarter ending 2025-09-30 was $1.48B, a 16.00% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. research and development expense for fiscal 2025 was $5.85B, a 13.99% increase from fiscal 2024.
- REGENERON PHARMACEUTICALS, INC. research and development expense for fiscal 2024 was $5.13B, a 15.61% increase from fiscal 2023.
- REGENERON PHARMACEUTICALS, INC. research and development expense for fiscal 2023 was $4.44B, a 23.56% increase from fiscal 2022.
- REGENERON PHARMACEUTICALS, INC. research and development expense for fiscal 2022 was $3.59B, a 25.61% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.63B 10-Q · filed 2026-07-30 | $3.18B 10-Q · filed 2026-07-30 | $4.80B derived: sum of 3 quarters · filed 2026-07-30 | $6.28B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2026-03-31 | $1.54B 10-Q · filed 2026-04-29 | $3.17B derived: sum of 2 quarters · filed 2026-04-29 | $4.64B derived: sum of 3 quarters · filed 2026-04-29 | $6.07B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-12-31 | $1.63B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $3.10B derived: sum of 2 quarters · filed 2026-02-04 | $4.52B derived: sum of 3 quarters · filed 2026-07-30 | $5.85B 10-K · filed 2026-02-04 | ||||
| 2025-09-30 | $1.48B 10-Q · filed 2025-10-28 | $2.90B derived: sum of 2 quarters · filed 2026-07-30 | $4.22B 10-Q · filed 2025-10-28 | $5.64B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-06-30 | $1.42B 10-Q · filed 2026-07-30 | $2.75B 10-Q · filed 2026-07-30 | $4.16B derived: sum of 3 quarters · filed 2026-07-30 | $5.43B derived: sum of 4 quarters · filed 2026-07-30 | ||||
| 2025-03-31 | $1.33B 10-Q · filed 2026-04-29 | $2.74B derived: sum of 2 quarters · filed 2026-04-29 | $4.01B derived: sum of 3 quarters · filed 2026-04-29 | $5.21B derived: sum of 4 quarters · filed 2026-04-29 | ||||
| 2024-12-31 | $1.41B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $2.68B derived: sum of 2 quarters · filed 2026-02-04 | $3.88B derived: sum of 3 quarters · filed 2026-02-04 | $5.13B 10-K · filed 2026-02-04 | ||||
| 2024-09-30 | $1.27B 10-Q · filed 2025-10-28 | $2.47B derived: sum of 2 quarters · filed 2025-10-28 | $3.72B 10-Q · filed 2025-10-28 | $4.90B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-06-30 | $1.20B 10-Q · filed 2025-08-01 | $2.45B 10-Q · filed 2025-08-01 | $3.63B derived: sum of 3 quarters · filed 2026-02-04 | $4.70B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2024-03-31 | $1.25B 10-Q · filed 2025-04-29 | $2.43B derived: sum of 2 quarters · filed 2026-02-04 | $3.50B derived: sum of 3 quarters · filed 2026-02-04 | $4.59B derived: sum of 4 quarters · filed 2026-02-04 | ||||
| 2023-12-31 | $1.18B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-04 | $2.25B derived: sum of 2 quarters · filed 2026-02-04 | $3.34B derived: sum of 3 quarters · filed 2026-02-04 | $4.44B 10-K · filed 2026-02-04 | ||||
| 2023-09-30 | $1.08B 10-Q · filed 2024-10-31 | $2.16B derived: sum of 2 quarters · filed 2024-10-31 | $3.26B 10-Q · filed 2024-10-31 | $4.30B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-06-30 | $1.09B 10-Q · filed 2024-08-01 | $2.19B 10-Q · filed 2024-08-01 | $3.23B derived: sum of 3 quarters · filed 2025-02-05 | $4.14B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2023-03-31 | $1.10B 10-Q · filed 2024-05-02 | $2.14B derived: sum of 2 quarters · filed 2025-02-05 | $3.06B derived: sum of 3 quarters · filed 2025-02-05 | $3.85B derived: sum of 4 quarters · filed 2025-02-05 | ||||
| 2022-12-31 | $1.04B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-05 | $1.95B derived: sum of 2 quarters · filed 2025-02-05 | $2.75B derived: sum of 3 quarters · filed 2025-02-05 | $3.59B 10-K · filed 2025-02-05 | ||||
| 2022-09-30 | $911.30M 10-Q · filed 2023-11-02 | $1.71B derived: sum of 2 quarters · filed 2023-11-02 | $2.55B 10-Q · filed 2023-11-02 | $3.29B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-06-30 | $794.30M 10-Q · filed 2023-08-03 | $1.64B 10-Q · filed 2023-08-03 | $2.38B derived: sum of 3 quarters · filed 2024-02-05 | $3.04B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2022-03-31 | $843.80M 10-Q · filed 2023-05-04 | $1.58B derived: sum of 2 quarters · filed 2024-02-05 | $2.25B derived: sum of 3 quarters · filed 2024-02-05 | $2.96B derived: sum of 4 quarters · filed 2024-02-05 | ||||
| 2021-12-31 | $737.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-05 | $1.40B derived: sum of 2 quarters · filed 2024-02-05 | $2.12B derived: sum of 3 quarters · filed 2024-02-05 | $2.86B 10-K · filed 2024-02-05 | $2.91B 10-K · filed 2022-02-07 | |||
| 2021-09-30 | $665.40M 10-Q · filed 2022-11-03 | $1.38B derived: sum of 2 quarters · filed 2022-11-03 | $2.12B 10-Q · filed 2022-11-03 | $2.78B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-06-30 | $714.20M 10-Q · filed 2022-08-03 | $1.46B 10-Q · filed 2022-08-03 | $2.11B derived: sum of 3 quarters · filed 2023-02-06 | $2.80B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2021-03-31 | $742.90M 10-Q · filed 2022-05-04 | $1.40B derived: sum of 2 quarters · filed 2023-02-06 | $2.08B derived: sum of 3 quarters · filed 2023-02-06 | $2.81B derived: sum of 4 quarters · filed 2023-02-06 | ||||
| 2020-12-31 | $656.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-06 | $1.34B derived: sum of 2 quarters · filed 2023-02-06 | $2.06B derived: sum of 3 quarters · filed 2023-02-06 | $2.65B 10-K · filed 2023-02-06 | $2.73B 10-K · filed 2021-02-08 | |||
| 2020-09-30 | $684.60M 10-Q · filed 2021-11-04 | $1.41B derived: sum of 2 quarters · filed 2021-11-04 | $1.99B 10-Q · filed 2021-11-04 | $2.54B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-06-30 | $722.00M 10-Q · filed 2021-08-05 | $1.31B 10-Q · filed 2021-08-05 | $1.86B derived: sum of 3 quarters · filed 2022-02-07 | $2.38B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2020-03-31 | $583.90M 10-Q · filed 2021-05-06 | $1.14B derived: sum of 2 quarters · filed 2022-02-07 | $1.66B derived: sum of 3 quarters · filed 2022-02-07 | $2.55B derived: sum of 4 quarters · filed 2022-02-07 | ||||
| 2019-12-31 | $552.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-07 | $1.08B derived: sum of 2 quarters · filed 2022-02-07 | $1.96B derived: sum of 3 quarters · filed 2022-02-07 | $2.45B 10-K · filed 2022-02-07 | $3.04B 10-K · filed 2020-02-07 | |||
| 2019-09-30 | $526.00M 10-Q · filed 2020-11-05 | $663.40M 10-Q · filed 2019-11-05 | $1.41B derived: sum of 2 quarters · filed 2020-11-05 | $1.90B 10-Q · filed 2020-11-05 | $2.35B 10-Q · filed 2019-11-05 | $1.78B derived: sum of 4 quarters · filed 2021-02-08 | ||
| 2019-06-30 | $885.50M 10-Q · filed 2020-08-05 | $1.05B 10-Q · filed 2019-08-06 | $1.37B 10-Q · filed 2020-08-05 | $1.69B 10-Q · filed 2019-08-06 | $1.26B derived: sum of 3 quarters · filed 2021-02-08 | $1.81B derived: sum of 4 quarters · filed 2021-02-08 | ||
| 2019-03-31 | $486.10M 10-Q · filed 2020-05-05 | $641.80M 10-Q · filed 2019-05-07 | $370.10M derived: sum of 2 quarters · filed 2021-02-08 | $927.10M derived: sum of 3 quarters · filed 2021-02-08 | $1.46B derived: sum of 4 quarters · filed 2021-02-08 | |||
| 2018-12-31 | -$116.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-08 | $441.00M derived: sum of 2 quarters · filed 2021-02-08 | $970.30M derived: sum of 3 quarters · filed 2021-02-08 | $1.47B 10-K · filed 2021-02-08 | $2.19B 10-K · filed 2019-02-07 | |||
| 2018-09-30 | $557.00M 10-Q · filed 2019-11-05 | $556.97M 10-Q · filed 2018-11-06 | $1.09B derived: sum of 2 quarters · filed 2019-11-05 | $1.58B 10-Q · filed 2019-11-05 | $1.58B 10-Q · filed 2018-11-06 | $2.11B derived: sum of 4 quarters · filed 2020-02-07 | ||
| 2018-06-30 | $529.30M 10-Q · filed 2019-08-06 | $529.29M 10-Q · filed 2018-08-02 | $1.03B 10-Q · filed 2019-08-06 | $1.03B 10-Q · filed 2018-08-02 | $1.56B derived: sum of 3 quarters · filed 2020-02-07 | $2.09B derived: sum of 4 quarters · filed 2020-02-07 | ||
| 2018-03-31 | $498.60M 10-Q · filed 2019-05-07 | $498.59M 10-Q · filed 2018-05-03 | $1.03B derived: sum of 2 quarters · filed 2020-02-07 | $1.56B derived: sum of 3 quarters · filed 2020-02-07 | $2.07B derived: sum of 4 quarters · filed 2020-02-07 | |||
| 2017-12-31 | $527.94M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-07 | $1.06B derived: sum of 2 quarters · filed 2020-02-07 | $1.57B derived: sum of 3 quarters · filed 2020-02-07 | $2.08B 10-K · filed 2020-02-07 | $2.08B 10-K · filed 2018-02-08 | |||
| 2017-09-30 | $529.75M 10-Q · filed 2018-11-06 | $1.04B derived: sum of 2 quarters · filed 2018-11-06 | $1.55B 10-Q · filed 2018-11-06 | $2.03B derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-06-30 | $509.98M 10-Q · filed 2018-08-02 | $1.02B 10-Q · filed 2018-08-02 | $1.50B derived: sum of 3 quarters · filed 2019-02-07 | $2.04B derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2017-03-31 | $507.44M 10-Q · filed 2018-05-03 | $986.65M derived: sum of 2 quarters · filed 2019-02-07 | $1.53B derived: sum of 3 quarters · filed 2019-02-07 | $2.09B derived: sum of 4 quarters · filed 2019-02-07 | ||||
| 2016-12-31 | $479.21M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-07 | $1.02B derived: sum of 2 quarters · filed 2019-02-07 | $1.58B derived: sum of 3 quarters · filed 2019-02-07 | $2.05B 10-K · filed 2019-02-07 | $2.05B 10-K · filed 2017-02-09 | |||
| 2016-09-30 | $543.05M 10-Q · filed 2017-11-08 | $1.10B derived: sum of 2 quarters · filed 2017-11-08 | $1.57B 10-Q · filed 2017-11-08 | $2.03B derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-06-30 | $559.93M 10-Q · filed 2017-08-03 | $1.03B 10-Q · filed 2017-08-03 | $1.49B derived: sum of 3 quarters · filed 2018-02-08 | $1.92B derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2016-03-31 | $470.11M 10-Q · filed 2017-05-04 | $931.32M derived: sum of 2 quarters · filed 2018-02-08 | $1.36B derived: sum of 3 quarters · filed 2018-02-08 | $1.75B derived: sum of 4 quarters · filed 2018-02-08 | ||||
| 2015-12-31 | $461.21M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $887.13M derived: sum of 2 quarters · filed 2018-02-08 | $1.28B derived: sum of 3 quarters · filed 2018-02-08 | $1.62B 10-K · filed 2018-02-08 | ||||
| 2015-09-30 | $425.92M 10-Q · filed 2016-11-04 | $816.25M derived: sum of 2 quarters · filed 2016-11-04 | $1.16B 10-Q · filed 2016-11-04 | $1.51B derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-06-30 | $390.33M 10-Q · filed 2016-08-04 | $733.44M 10-Q · filed 2016-08-04 | $1.09B derived: sum of 3 quarters · filed 2017-02-09 | $1.42B derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2015-03-31 | $343.11M 10-Q · filed 2016-05-05 | $694.86M derived: sum of 2 quarters · filed 2017-02-09 | $1.03B derived: sum of 3 quarters · filed 2017-02-09 | $1.33B derived: sum of 4 quarters · filed 2017-02-09 | ||||
| 2014-12-31 | $351.75M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $689.47M derived: sum of 2 quarters · filed 2017-02-09 | $983.97M derived: sum of 3 quarters · filed 2017-02-09 | $1.27B 10-K · filed 2017-02-09 | ||||
| 2014-09-30 | $337.73M 10-Q · filed 2015-11-04 | $632.23M derived: sum of 2 quarters · filed 2015-11-04 | $919.61M 10-Q · filed 2015-11-04 | $1.19B derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-06-30 | $294.50M 10-Q · filed 2015-08-04 | $581.88M 10-Q · filed 2015-08-04 | $850.02M derived: sum of 3 quarters · filed 2016-02-11 | $1.07B derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2014-03-31 | $287.38M 10-Q · filed 2015-05-07 | $555.52M derived: sum of 2 quarters · filed 2016-02-11 | $779.56M derived: sum of 3 quarters · filed 2016-02-11 | $967.03M derived: sum of 4 quarters · filed 2016-02-11 | ||||
| 2013-12-31 | $268.14M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $492.19M derived: sum of 2 quarters · filed 2016-02-11 | $679.65M derived: sum of 3 quarters · filed 2016-02-11 | $859.95M 10-K · filed 2016-02-11 | ||||
| 2013-09-30 | $224.04M 10-Q · filed 2014-11-04 | $411.51M derived: sum of 2 quarters · filed 2014-11-04 | $591.81M 10-Q · filed 2014-11-04 | $772.83M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-06-30 | $187.46M 10-Q · filed 2014-08-05 | $367.76M 10-Q · filed 2014-08-05 | $548.79M derived: sum of 3 quarters · filed 2015-02-12 | $707.08M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2013-03-31 | $180.30M 10-Q · filed 2014-05-08 | $361.32M derived: sum of 2 quarters · filed 2015-02-12 | $519.62M derived: sum of 3 quarters · filed 2015-02-12 | $666.99M derived: sum of 4 quarters · filed 2015-02-12 | ||||
| 2012-12-31 | $181.02M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $339.32M derived: sum of 2 quarters · filed 2015-02-12 | $486.69M derived: sum of 3 quarters · filed 2015-02-12 | $625.55M 10-K · filed 2015-02-12 | ||||
| 2012-09-30 | $158.29M 10-Q · filed 2013-11-05 | $305.67M derived: sum of 2 quarters · filed 2013-11-05 | $444.53M 10-Q · filed 2013-11-05 | $573.57M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-06-30 | $147.37M 10-Q · filed 2013-08-06 | $286.24M 10-Q · filed 2013-08-06 | $415.28M derived: sum of 3 quarters · filed 2014-02-13 | $543.20M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2012-03-31 | $138.86M 10-Q · filed 2013-05-03 | $267.90M derived: sum of 2 quarters · filed 2014-02-13 | $395.83M derived: sum of 3 quarters · filed 2014-02-13 | $538.98M derived: sum of 4 quarters · filed 2014-02-13 | ||||
| 2011-12-31 | $129.04M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | $256.96M derived: sum of 2 quarters · filed 2014-02-13 | $400.11M derived: sum of 3 quarters · filed 2014-02-13 | $529.51M 10-K · filed 2014-02-13 | ||||
| 2011-09-30 | $127.92M 10-Q · filed 2012-10-24 | $271.07M derived: sum of 2 quarters · filed 2012-10-24 | $400.46M 10-Q · filed 2012-10-24 | $525.68M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-06-30 | $143.15M 10-Q · filed 2012-07-25 | $272.54M 10-Q · filed 2012-07-25 | $397.75M derived: sum of 3 quarters · filed 2013-02-15 | $519.80M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2011-03-31 | $129.39M 10-Q · filed 2012-04-26 | $254.60M derived: sum of 2 quarters · filed 2013-02-15 | $376.65M derived: sum of 3 quarters · filed 2013-02-15 | $501.17M derived: sum of 4 quarters · filed 2013-02-15 | ||||
| 2010-12-31 | $125.21M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $247.25M derived: sum of 2 quarters · filed 2013-02-15 | $371.78M derived: sum of 3 quarters · filed 2013-02-15 | $489.25M 10-K · filed 2013-02-15 | ||||
| 2010-09-30 | $122.04M 10-Q · filed 2011-10-27 | $246.57M derived: sum of 2 quarters · filed 2011-10-27 | $364.04M 10-Q · filed 2011-10-27 | $482.83M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-06-30 | $124.53M 10-Q · filed 2011-07-28 | $242.00M 10-Q · filed 2011-07-28 | $360.79M derived: sum of 3 quarters · filed 2012-02-21 | $466.22M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2010-03-31 | $117.47M 10-Q · filed 2011-05-03 | $236.26M derived: sum of 2 quarters · filed 2012-02-21 | $341.69M derived: sum of 3 quarters · filed 2012-02-21 | $435.93M derived: sum of 4 quarters · filed 2012-02-21 | ||||
| 2009-12-31 | $118.79M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-21 | $224.22M derived: sum of 2 quarters · filed 2012-02-21 | $318.45M derived: sum of 3 quarters · filed 2012-02-21 | $398.76M 10-K · filed 2012-02-21 | ||||
| 2009-09-30 | $105.43M 10-Q · filed 2010-10-28 | $199.66M derived: sum of 2 quarters · filed 2010-10-28 | $279.97M 10-Q · filed 2010-10-28 | |||||
| 2009-06-30 | $94.23M 10-Q · filed 2010-07-28 | $174.54M 10-Q · filed 2010-07-28 | ||||||
| 2008-12-31 | $274.90M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |